These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 22364810)
1. Harnessing γδ T cells in anticancer immunotherapy. Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810 [TBL] [Abstract][Full Text] [Related]
2. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Gomes AQ; Martins DS; Silva-Santos B Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627 [TBL] [Abstract][Full Text] [Related]
3. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside. Braza MS; Klein B Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882 [TBL] [Abstract][Full Text] [Related]
4. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies. Martinet L; Poupot R; Fournié JJ Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas. Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935 [TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach. Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791 [TBL] [Abstract][Full Text] [Related]
7. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372 [TBL] [Abstract][Full Text] [Related]
8. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Viey E; Laplace C; Escudier B Expert Rev Anticancer Ther; 2005 Dec; 5(6):973-86. PubMed ID: 16336088 [TBL] [Abstract][Full Text] [Related]
9. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Bonneville M; Scotet E Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417 [TBL] [Abstract][Full Text] [Related]
10. γδ T-cell conference 2012: close encounters for the fifth time. Silva-Santos B; Schamel WW; Fisch P; Eberl M Eur J Immunol; 2012 Dec; 42(12):3101-5. PubMed ID: 23255005 [TBL] [Abstract][Full Text] [Related]
11. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells. Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model. Devaud C; Bilhere E; Loizon S; Pitard V; Behr C; Moreau JF; Dechanet-Merville J; Capone M Cancer Res; 2009 May; 69(9):3971-8. PubMed ID: 19383918 [TBL] [Abstract][Full Text] [Related]
13. Development and function of interleukin 17-producing γδ T cells. Korn T; Petermann F Ann N Y Acad Sci; 2012 Jan; 1247():34-45. PubMed ID: 22239719 [TBL] [Abstract][Full Text] [Related]
14. Harnessing the power of Vδ2 cells in cancer immunotherapy. Fowler DW; Bodman-Smith MD Clin Exp Immunol; 2015 Apr; 180(1):1-10. PubMed ID: 25469879 [TBL] [Abstract][Full Text] [Related]
15. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635 [TBL] [Abstract][Full Text] [Related]
16. [γδ T cell-based cancer immunotherapy]. Matsushita H; Kakimi K Nihon Rinsho; 2017 Feb; 75(2):301-305. PubMed ID: 30562868 [TBL] [Abstract][Full Text] [Related]
17. [Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate]. Kimura S Clin Calcium; 2008 Apr; 18(4):499-505. PubMed ID: 18379032 [TBL] [Abstract][Full Text] [Related]
18. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998 [TBL] [Abstract][Full Text] [Related]
19. Role of γδ T cells in α-galactosylceramide-mediated immunity. Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194 [TBL] [Abstract][Full Text] [Related]
20. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy. Rei M; Pennington DJ; Silva-Santos B Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]